Seeking Alpha

Gilead Sciences Inc. (GILD)

()

News & PR
Market Currents

Buzz
Twitter: GILD

Business Intelligence
Transcripts
Events
Key Developments

Analysis - Latest Articles by most recent | most commented

Ten Top Companies Attracting Interest from BetterInvesting Members

Dec 21 • David I. Templeton • 1 Comment
This Week's Failed Trials, Missed Targets in Biotech

Dec 20 • The Burrill Report • 1 Comment
Gilead: Little to Show After Cardiovascular Push

Dec 15 • EP Vantage • Comment!
Wall Street Breakfast: Must-Know News

Dec 15 • SA Editor Eli Hoffmann • 16 Comments
Will 2009's Losers Become 2010's Winners?

Dec 14 • Alan Brochstein • 6 Comments
Gilead Closer to FDA Approval for CF Drug

Dec 13 • Zacks.com • Comment!
China Biotech Week in Review: Two More R&D Centers, One PE Fund, One IPO

Nov 30 • ChinaBio Today • 2 Comments
8 HealthCare Stocks with 3%+ Dividends

Nov 29 • Hao Jin • 9 Comments
Is Tech Overvalued?

Nov 22 • Hao Jin • 4 Comments
Connor Browne: Asset Allocation Is Key in Current Environment

Nov 18 • Benjamin Shepherd • Comment!
Evaluating S&P 500's Top Ten CEOs

Nov 11 • Value Expectations • 3 Comments
Healthcare Profits: Assessing Company Sensitivity to Obamacare

Oct 30 • Richard Shaw • 11 Comments
Weekly Street Sentiment: Market Prepares for ‘Trick or Treat’

Oct 27 • First Coverage • Comment!
Today's Notable Market Action

Oct 22 • The Pragmatic Capitalist • Comment!
Gilead Sciences Is in Great Health

Oct 21 • Ockham Research • 2 Comments
Wall Street Breakfast: Must-Know News

Oct 21 • SA Editor Eli Hoffmann • 7 Comments
Four ETFs with Great Apple Exposure

Oct 20 • ETF Daily News • 1 Comment
An Earnings Season Options Strategy

Oct 19 • Marco Hickey • 4 Comments
Biotech: Q3 Market Update

Oct 16 • R. Scott Raynovich • 1 Comment
Consensus Analyst Stock Ratings Creep Up

Oct 12 • Bespoke Investment Group • Comment!
What Do the Schizophrenic Markets Want?

Sep 23 • David Brown • 12 Comments
15 Stocks That Are Having a Tough Quarter, But Are Still Worth a Look

Sep 20 • Alan Brochstein • 7 Comments
Maverick Capital: Buying Up Computer Hardware, Drug Companies and Banks

Sep 11 • Todd Walker • Comment!
Taking Profits from Swine Flu with Tamiflu

Sep 10 • Ockham Research • 2 Comments
Ken Griffin's Citadel Fund: Options Eye Candy

Sep 10 • Market Folly • 2 Comments
Gilead Sciences: Expect Share Price to Move Up

Sep 4 • Hans Wagner • Comment!
Why Health Insurers Make Lousy Villains

Aug 26 • Rick Newman • 3 Comments
Moore Capital Is Buying: China, Financials and Consumer Staples

Aug 20 • Todd Walker • Comment!
3 Biotechs, 3 Big Pharma Plays for the Coming Generics Boom

Aug 18 • The Curious Investor • 4 Comments
Onyx Pharmaceuticals: Good Reasons for Raising Capital, Investors Overly Concerned

Aug 13 • Raymond Chung • 2 Comments
Market Sentiment: Sell-Side Awaits Catalyst

Aug 11 • First Coverage • Comment!
Using Put Options to Purchase Big Techs for Less

Aug 6 • Marco Hickey • Comment!
Time to Get Conservative? 50 Ideas for a Summer Sell-Off

Aug 3 • Marco Hickey • 16 Comments
CEL-SCI's Flu Work: Diligent Preparation, Promising Results

Jul 30 • M. E. Garza • 5 Comments
Tuesday Options Recap

Jul 28 • Frederic Ruffy • Comment!
20 Option Ideas for This Market

Jul 28 • Marco Hickey • Comment!
Too Late to Board the Biotech Bandwagon?

Jul 28 • Sam Subramanian • 5 Comments
Analyzing Earnings Quality of Companies Set to Report

Jul 23 • Value Expectations • Comment!
Wall Street Breakfast: Must-Know News

Jul 22 • SA Editor Rachael Granby • 13 Comments
King Pharma: FDA Should Like Corvue - And So Will Investors

Jul 20 • Kaushik Paul • 2 Comments
Schering's HIV Drug Moves Further Along the Pipeline

Jul 17 • Zacks.com • 2 Comments

Gilead Sciences Inc. (GILD)

Analysis - Latest Articles by most recent | most commented

The Seeking Alpha 100

Fastest Climbers

Top Commenters

Top Instabloggers

Top StockTalkers